Literature DB >> 8266108

Toxic oil syndrome and eosinophilia-myalgia syndrome: May 8-10, 1991, World Health Organization meeting report.

R M Philen1, M Posada.   

Abstract

In May 1991, researchers and clinicians from throughout the world met at a workshop sponsored by the Regional Office for Europe of the World Health Organization in collaboration with the Fondo de Investigación Sanitaria, Spain, and the U.S. Food and Drug Administration, National Institutes of Health, National Institutes of Mental Health, and Centers for Disease Control and Prevention to share information about two very similar diseases--toxic oil syndrome and eosinophilia-myalgia syndrome. In this paper the interpretation of conference proceedings is presented, current knowledge of the two disorders is summarized, and some possible areas for future research are mentioned. Toxic oil syndrome and eosinophilia-myalgia syndrome have many similarities. Both are related to consumer products that were presumed to be safe but have been found to have numerous trace contaminants, many of which remain to be identified, including the etiologic agents of both disorders. Both illnesses affect patients clinically by causing intense, incapacitating myalgias and a marked peripheral eosinophilia. Other rheumatologic manifestations are common in both, including arthralgias, sicca syndrome, scleroderma-like skin changes, carpal tunnel syndrome, and joint contractures. No clinical or laboratory feature has been found to be pathognomonic of either disease, and accurate diagnosis rests on the clinical judgment of the attending physician. Deaths have occurred in both diseases, and the cumulative mortality for each is approximately 2.5% for the first 2 years. Long-term complications include pulmonary hypertension, peripheral neuropathies, and joint contractures. Although treatment with corticosteroids has resulted in significant symptomatic relief in persons with either disorder, it does not alter the clinical course or long-term outcome. Research into the etiologic agents, preferred treatments, and ways to avoid similar problems in the future is needed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8266108     DOI: 10.1016/s0049-0172(05)80017-4

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  6 in total

1.  Antiganglioside antibodies in toxic oil syndrome.

Authors:  C Iñguez; A Jiménez-Escrig; J Gobernado; G de Blas; M Nocito; M L del Villar; P Gonzalez-Porqué
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-07       Impact factor: 10.154

Review 2.  The toxic oil syndrome: an example of an exogenously induced autoimmune reaction. Toxic oil syndrome.

Authors:  S A Bell
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

3.  Geographic disparity in systemic sclerosis mortality in the United States: 1999-2017.

Authors:  Alicia Rodriguez-Pla; Robert W Simms
Journal:  J Scleroderma Relat Disord       Date:  2019-08-26

4.  Possible etiologic agents for toxic oil syndrome: fatty acid esters of 3-(N-phenylamino)-1,2-propanediol.

Authors:  R H Hill; H H Schurz; M Posada de la Paz; I Abaitua Borda; R M Philen; E M Kilbourne; S L Head; S L Bailey; W J Driskell; J R Barr
Journal:  Arch Environ Contam Toxicol       Date:  1995-02       Impact factor: 2.804

5.  Neurologic outcomes of toxic oil syndrome patients 18 years after the epidemic.

Authors:  Manuel Posada de la Paz; Rossanne M Philen; Fredric Gerr; Richard Letz; Maria José Ferrari Arroyo; Lydia Vela; Maravillas Izquierdo; Concepción Martín Arribas; Ignacio Abaitua Borda; Alejandro Ramos; Cristina Mora; Gloria Matesanz; Maria Teresa Roldán; Juan Pareja
Journal:  Environ Health Perspect       Date:  2003-08       Impact factor: 9.031

Review 6.  Rheumatic diseases induced by drugs and environmental factors: the state-of-the-art - part one.

Authors:  Karolina Niklas; Arkadiusz A Niklas; Dominik Majewski; Mariusz Puszczewicz
Journal:  Reumatologia       Date:  2016-07-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.